Regeneron IPR hearing suggests Eylea patent may be in trouble - analyst
Melpomenem


Regeneron's (NASDAQ:REGN) oral IPR hearing on the IPR on â338 MOU patent on Wednesday suggests that the company could lose the patent, according to Jefferies.
"We went into trial believing that REGN could lose the IPR on â338 MOU patent â the oral hearing yesterday reaffirms our views that Eylea could face biosimilar competition in 2024 (IPR decision ~Nov. 2022)," Jefferies analyst Akash Tewari wrote in a note.

REGN may lose the IPR on '338 patent on grounds of both anticipation and obviousness, according to Tewari, who has an underperform rating and $536 price target on Regeneron (REGN). Commentary from trial judges during the hearing seems to be leaning towards Mylan, now called Viatris (NASDAQ:VTRS), particularly on teachings from Dixon around Eylea sequence.
Recall in November The U.S. Patent and Trademark Office's Patent Trial and Review Board said it will review two patents related to Regeneron (REGN) Eylea amid a challenge from Viatris (VTRS).